This region represents the single largest revenue contributor in the Commercial Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen supplies well-established local brands, as well as internationally recognised medicines across multiple countries in the region, supported by commercial and sales employees. Extensive and differentiated manufacturing capabilities including high potency and hormonal solids, vaccines and other state-of-the-art sterile capabilities exist at one of the Group’s primary manufacturing sites in Gqeberha, South Africa. This primary site is complemented by five regional sites across the continent.

Aspen’s presence in the Americas is dominated by the businesses in Latin America. Mexico and Brazil are the largest contributors to regional performance. Aspen provides a range of trusted brands across prescription, hospital and over-the-counter medicines and operates one finished dose form manufacturing facility in Brazil.

This region comprises all Asian territories where we sell products, including China. Active trading subsidiaries include those in China, the Philippines, Taiwan and Malaysia with other countries in the region reached via distributors. Sterile Focus Brands are the key contributor to revenue. Our manufacturing facility in India is our primary new product development site.

One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets.

Europe CIS provides a broad range of Sterile Focus and Regional Brands while operating a range of manufacturing facilities for Aspen’s own production needs, as well as manufacturing for third parties. Sterile Focus Brands comprise anaesthetics and thrombosis in Russia and the other CIS countries only. Manufacturing activities include active pharmaceutical ingredients and finished dose form production and our sites are widely accredited. The prefilled syringe and multi-dose form sites in France and Germany respectively, provide finished dose form medicines for commercialisation by Aspen and third parties for both domestic and export markets.